Photo courtesy of Longfellow Real Estate Partners

What: Vor Biopharma clinical manufacturing facility
Where: 100 Cambridgepark Drive, Cambridge
Built: 2021-2022
Owner: Longfellow Real Estate Partners 

Vor Biopharma will expand at 100 Cambridgepark Drive with the construction of an in-house clinical manufacturing facility, growing its footprint to 75,000 square feet on three floors. 

100 Cambridgepark Drive is part of a three-building, 609,000-square-foot portfolio in Cambridge’s Alewife section acquired by Longfellow Real Estate Partners and Morgan Stanley in 2017 for $370 million. 

Vor originally leased 33,000 square feet of office and lab space in 2019 at the property, becoming the first biotech tenant of the campus. The publicly-traded company is researching stem cell therapies for cancer treatments. 

Cresa Boston’s Paul Delaney and John Coakley represented Vor in the latest lease transaction, while Newmark represented ownership. 

They Said It: 

“Two years ago, Cresa identified numerous locations for us to consider when we first thought of relocating to support our expansion plans, and ultimately helped us secure the right space at 100 Cambridgepark Drive.” 

— Stefan Chios, facilities manager, Vor Pharmaceuticals